Physiologic Changes of Posterior Ocular Segment During the Menstrual Cycle

Retinal Vascular Clinical Trial

Official title:

Physiologic Changes of Posterior Ocular Segment During the Menstrual Cycle

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04731207
• Other study ID #: HE631585
• Status: Recruiting
• Phase: N/A
• Start date: September 3, 2021
• Est. completion date: December 30, 2023

Study information

• Verified date: October 2023
• Source: Khon Kaen University
• Contact: Suthasinee Sinawat, MD
• Phone: +66 81 5454594
• Email: ssuthasinee[@]kku.ac.th
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Changes of luteinizing hormone (LH), estrogen and progesterone during the menstrual cycle influence the ocular physiology in both anterior and posterior segments. From the literature review, there were no significant differentiation in tear physiology, anterior chamber dept, lens thickness and refractive status. Some studies demonstrated then the central corneal thickness was thinner in the follicular phase, but this is non-conclusive. Advance in ophthalmic technologies provide few studies of posterior segment changes during the menstrual cycle, however, there were quite difference in methodology such as detection methods of ovulation.

Description:

There were 2 studies of posterior segment changes during the menstrual cycle. Akar et al showed significant decrease of neuroretinal rim area and increase of cupt area in late luteal phase. Ulas et al found that choroidal thickness was significant thicker in mid-luteal phase. However, the study of retinal vascular density by optical coherence tomography angiography (OCTA) during the menstrual cycle has never been published before.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 39
• Est. completion date: December 30, 2023
• Est. primary completion date: December 30, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 25 Years to 40 Years

Eligibility

Inclusion Criteria:

• Female with age 25-40 yr
• Normal body mass index (18.5-24.9)
• Regular menstrual cycle (28-32 days)
• Written informed consent

Exclusion Criteria:

• Pregnant women
• Lactating women
• Having childbirth or miscarriage within 6 months
• Systemic diseases which need taking the regular medication
• History of ocular disease such as glaucoma, retinal vascular diseases and macular disease
• History of hormonal taking such as oral contraceptive pills within 6 months
• History of intraocular laser and intraocular surgery
• Refractive error; spherical equivalent >4 diopters
• Can not taking the images by Optovue® such as spine diseases Withdrawal criteria
• Pregnancy detection during the study period
• Receiving sex hormone during the study period such as emergency contraceptive pills

Related Conditions & MeSH terms

• Retinal Vascular

Intervention

Device:
• Optovue®
Optical coherence tomography and optical coherece tomography angiography

Locations

Country	Name	City	State
Thailand	Khon Kaen University	Khon Kaen

Sponsors (1)

Lead Sponsor	Collaborator
Khon Kaen University

Country where clinical trial is conducted

Thailand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Retinal vascular density	% of retinal vascular density is measured by optical coherence tomography angiography	1 month
Secondary	Choroidal thickness	Choroidal thickness (um) is measured by optical coherence tomography	1 month
Secondary	Retinal nerve fiber layer thickness	Retinal nerve fiber layer thickness (um) is measured by optical coherence tomography	1 month
Secondary	Optic nerve head topography	Disc area and cup area (mm3) are measured by optical coherence tomography	1 month